Amylyx Pharmaceuticals, Inc. (AMLX) FinancialsAMLXAmylyx Pharmaceuticals, Inc.

Evaluating the bottom line, Amylyx Pharmaceuticals, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -74.73%, provide a clear picture of how effectively AMLX converts its operational activities into shareholder value.

In the context of the broader market, AMLX competes directly with industry leaders such as INDV and MANE. With a market capitalization of $2.41B, it holds a significant position in the sector. When comparing efficiency, AMLX's gross margin of N/A stands against INDV's 85.42% and MANE's N/A. Such benchmarking helps identify whether Amylyx Pharmaceuticals, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a gross margin of 63.22% for Q4 2024, indicating a recovery from previous losses, and a current ratio of 17.85, showing strong liquidity.